Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels
US9895400B2 · kind B2 · utility
0Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 10, 2015 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | Mar 11, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/225
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.